Travelgum

Quick links

Choose a section

Quick links to important sections

Advertisements

Travelgum

Advertisements
Advertisements

Method of action: Antiemetic

Advertisements

Overview of Travelgum

Quick Facts

Property Description
Active Ingredient Dimenhydrinate
Form Medicated Chewing Gum
Pharmacological Class Antihistamine (H1-receptor antagonist), Anti-emetic Agent
General Purpose Relief from motion sickness symptoms
Origin Synthetic Compound

What Type of Medicine is Travelgum?

Travelgum is a proprietary pharmaceutical preparation whose active ingredient is Dimenhydrinate, which is a synthetic compound classified primarily as a first-generation antihistamine and a dedicated anti-emetic agent. The Dimenhydrinate molecule is chemically recognized as a salt derived from two components, Diphenhydramine and 8-Chlorotheophylline.

Dimenhydrinate is an ethanolamine derivative used to prevent and treat motion sickness and vertigo. This class of drug is used to suppress motion-induced symptoms, serving as a key over-the-counter (OTC) option for travelers. This classification means the medicine works by moderating the body's internal signals that cause dizziness and nausea.


Travelgum's Unique Form and Primary Purpose

Travelgum is presented in the distinctive dosage form of a Medicated Chewing Gum, designed for drug delivery via the Oral Mucosal Route. This form allows the Dimenhydrinate to be released and absorbed directly through the mouth's lining while chewing. Dimenhydrinate is utilized for the prophylaxis and symptomatic treatment of motion sickness.

Therefore, the fundamental general therapeutic purpose of this preparation is to proactively reduce or diminish the feelings of nausea, vomiting, and vertigo that occur during various forms of travel. This unique administration method offers a convenient, water-free option, which is particularly beneficial when managing symptoms during transport where immediate access to water or traditional swallowing may be difficult.

Regulatory References

  1. MedlinePlus Drug Information
  2. Health Canada Drug Product Database
Advertisements

What side effects are possible with Travelgum?

Possible Side Effects and Safety Information

Regulatory documentation for Dimenhydrinate details possible adverse reactions categorized by frequency and the physiological systems affected, in alignment with official safety classification standards. The official safety profile is predominantly characterized by effects on the central nervous system (CNS) and anticholinergic actions.

Adverse Reactions Classified by Frequency

The most frequently documented effects are classified as Very Common and include drowsiness and sedation. Reactions listed as Common often relate to anticholinergic effects and include headache, dizziness, dry mouth, constipation, and blurred vision. Less frequent effects, such as nausea, vomiting, tachycardia, or urinary retention, are categorized as Uncommon.

Systemic Safety Patterns

Adverse reactions are formally grouped into System-Organ Classes. Effects documented under Nervous System Disorders are the most common. Gastrointestinal Disorders (e.g., dry mouth) and Eye Disorders (e.g., blurred vision) reflect the drug's anticholinergic properties.

Serious and Population-Specific Considerations

Regulatory labels document the potential, though rare, occurrence of serious adverse reactions, including convulsions/seizures and certain blood dyscrasias. Furthermore, official safety data note that certain groups may experience heightened effects: older adults show increased sensitivity to sedation and anticholinergic effects, and children may exhibit the risk of paradoxical excitation. Safety limitations also restrict use in conditions sensitive to anticholinergic action, such as narrow-angle glaucoma and prostatic hypertrophy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Dimenhydrinate may lead to two primary, officially documented clusters of manifestations: Central Nervous System (CNS) depression, presenting as drowsiness, profound sedation, or coma; and CNS excitation, which is particularly likely in pediatric patients and involves agitation, hallucinations, and seizures. Anticholinergic toxicity is also officially documented, characterized by signs such as mydriasis (fixed, dilated pupils), tachycardia (rapid heart rate), fever (pyrexia), and dry mouth.

The regulatory profile explicitly identifies several life-threatening outcomes, including severe cardiac arrhythmias (such as QRS widening), respiratory depression, cardiovascular collapse, and potential death.

Required Emergency Actions

The official guidance from health authorities requires the public to seek immediate medical attention and contact a Poison Help line or emergency services immediately upon suspicion of overdose. Urgent medical evaluation is required if the patient is hallucinating, seizing, has trouble breathing, cannot be awakened, or has collapsed.

Management and Antidote Status

Regulatory documents state that no specific antidote is known for Dimenhydrinate overdosage. Treatment is defined as symptomatic and supportive care. Specific procedural interventions documented in regulatory information include gastric lavage, administration of activated charcoal, and the use of benzodiazepines to control convulsions. It is explicitly stated that emesis should not be induced (vomiting should not be caused). Continuous monitoring of vital signs and Electrocardiogram (ECG) activity is a required procedure following evaluation.

Advertisements

Therapeutic Uses of Travelgum

What Travelgum treats: main uses and benefits

Travelgum is a medication used for the symptomatic management of motion sickness (kinetosis), a condition where movement causes symptoms related to systemic imbalance. It is commonly used to help with the symptomatic relief of nausea, vomiting, and dizziness related to motion.


Therapeutic Scope and Application

This medication is applied across domains where additional symptomatic support is needed against conditions characterized by periods of heightened symptoms triggered by travel. Travelgum is relevant for easing symptom clusters that may appear suddenly or intensify, such as during long car rides, sea voyages, or air travel. The primary symptomatic relief areas include assistance with motion sickness, seasickness, and airsickness.


Patient Comfort and Function

This medication provides supportive relief for the core symptoms of motion sickness, particularly nausea and vomiting, which create noticeable physiological strain. A key benefit is that it supports the patient during episodes of heightened discomfort during travel. This supportive relief assists with supporting functional stability and may help patients cope more steadily with difficult episodes.

Quick Fact: Supportive Management for Motion-Induced Nausea

The medication may assist with easing temporary functional strain, which may support a more manageable experience during travel where symptoms could otherwise interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility for Travelgum (Dimenhydrinate): Official Regulatory Information

The eligibility to use Travelgum is strictly governed by age restrictions, known contraindications, and specific pre-existing medical conditions, as defined in official regulatory labeling.

Classification Population/Condition Restriction Status
Absolute Contraindication Children under 2 years of age Prohibited (Safety/efficacy not established)
Absolute Contraindication Known Hypersensitivity Prohibited (To Dimenhydrinate, Diphenhydramine, or 8-Chlorotheophylline)
Restricted Use Patients with narrow-angle glaucoma Caution Advised (Risk of aggravation)
Restricted Use Patients with prostatic enlargement Caution Advised (Risk of urinary retention)
Restricted Use Patients with chronic lung diseases Caution Advised (e.g., emphysema or chronic bronchitis)
Conditional Use Pregnant Women (Category B) Use only if clearly needed
Conditional Use Nursing Mothers Requires decision to discontinue drug or nursing (Excreted into breast milk)
Special Caution Older Adults (65+ years) Caution Advised (Increased sensitivity and risk of adverse effects)

Official documents establish that use is permitted for adults and children aged 2 years and older, with specific limitations applying to the pediatric and geriatric populations. Patients with certain conditions, such as hepatic impairment or seizure disorders, also require cautious use. The ultimate structure of eligibility is determined by these official, labeled restrictions.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction profile of Dimenhydrinate (Travelgum) based strictly on authoritative governmental regulatory documents.

Classification Regulatory Status or Interaction Basis
Formally Contraindicated Monoamine Oxidase Inhibitors (MAOIs). Must not be used concurrently, and the restriction typically extends for 1 to 2 weeks (or 14 days) after stopping MAOI therapy.
Pharmacodynamic Reinforcement Central Nervous System (CNS) Depressants, including sedatives, hypnotics, opioids, tranquilizers, and Alcohol. Co-administration may result in an additive sedative effect.
Increased Side Effects Anticholinergic Drugs, including tricyclic antidepressants and other antihistamines. Concomitant use may intensify anticholinergic side effects.
Symptom Masking Ototoxic Drugs (e.g., Aminoglycoside antibiotics). Dimenhydrinate may mask the early warning signs of ototoxicity induced by these medicines, a factor noted in official cautions.

The regulatory documentation primarily defines the product's interaction structure through the risks of additive pharmacological effects on the central and peripheral nervous systems. The prohibition of use with MAOIs is the most restrictive constraint, requiring specific timing separation. This profile highlights the need to assess concurrent medication use for substances that reinforce the known pharmacologic actions of Dimenhydrinate.

Advertisements

Mechanism of Action

H1 and M1 Receptor Antagonism

This domain covers the primary molecular action of dimenhydrinate (Travelgum), which involves centrally blocking histamine H1 and muscarinic acetylcholine M1 receptors. This antagonist effect suppresses key neurotransmitter signaling in the brain, directly contributing to CNS depression; the receptor blockade is intrinsically linked to the physiological consequence of somnolence.


Suppression of the Vestibular-Emetic Pathway

This mechanism focuses on how the central receptor antagonism translates into the core effect by inhibiting the Vestibular-Emetic Pathway. By reducing the transmission of nerve impulses from the vestibular system (inner ear's balance organs) to the Vomiting Center in the brainstem, this mechanism modifies the signal cascade that leads to the physiological outcome of vomiting (emesis).


Modulating Central Activation with Component Synergy

This domain addresses the drug's composition, where the stimulant component, 8-chlorotheophylline (an adenosine antagonist), is included to provide a mechanistic counter-modulation. The adenosine antagonism mechanism counter-modulates the CNS depression, influencing the overall physiological consequence of somnolence, which results in the physiological consequence of drowsiness that is an inherent physiological consequence of the H1 and M1 receptor blockade by the diphenhydramine component.

Advertisements

Dosage and Administration Information

How to Use Travelgum: Administration Guidelines

Travelgum (Dimenhydrinate 20 mg medicated chewing gum) is designed for systemic drug delivery via the Oral Mucosal Route. The instructions for its use are centered on specific timing, a defined chewing technique, and adherence to dose maximums.


Administration Scope

Element Description
Route of administration Oral Mucosal Route (absorption through the mouth's lining). The gum must not be swallowed.
Standard Dose Adults: 1 gum (20 mg). Maximum of 4 gums (80 mg) in 24 hours.
Prophylactic Timing The first dose is typically administered 15 to 30 minutes before the start of travel or the anticipated activity.
Dosing Interval Administration may be repeated after a minimum interval of 3 to 4 hours if symptoms persist.
Intake Condition May be used with or without the consumption of food.

Usage Procedure and Limits

The correct procedure for administration ensures the active substance is adequately released and absorbed. This method establishes the physical procedure necessary for the drug to enter the systemic circulation.

Classification Rule
Chewing Technique The gum must be chewed actively for 5 to 10 minutes. The remaining gum base must then be discarded.
Age-Specific Limits Children (4–12 years): Maximum of 2 gums (40 mg) in 24 hours. Not to be used in children under 4 years of age.
Frequency Pattern Intended for intermittent, as-needed use relative to specific travel episodes, rather than for continuous daily therapeutic cycles.

The following parameters define the standardized, time-dependent protocol for administering the medicine, establishing the necessary preparatory action (chewing) and the dose limits for use in specific age groups.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Travelgum


Research Evidence for Motion Sickness Prevention

Research exploring the active ingredient Dimenhydrinate has primarily focused on its use for motion sickness prophylaxis, meaning it was studied for the prevention of symptoms like nausea, vomiting, and dizziness when administered before exposure to travel. This area of study is observed in data, including randomized controlled trials (RCTs) and comprehensive systematic reviews. These study designs are relevant in trials assessing short-term or episodic symptom patterns.

These studies generally included healthy adults who were known to be susceptible to motion sickness. Research explored outcomes related to physical discomfort and systemic or functional imbalance, such as how frequently symptoms occurred and how intensely patients reported feeling nauseated on a standardized scale. The body of evidence, derived from multiple prophylactic trials, reported measurements of patterns related to the occurrence of motion sickness symptoms in individuals compared to those receiving a placebo during a defined travel event. This evidence contributes to understanding symptom patterns related to conditions characterized by acute or disruptive episodes triggered by motion.


Research Evidence for Vertigo and General Nausea

Research has also examined the use of Dimenhydrinate for conditions associated with acute or disruptive episodes of nausea or vertigo that are not caused by motion. The evidence in this area is generally composed of individual clinical trials, which are often smaller in size, and observational settings that evaluate symptom control.

These studies monitored outcomes related to patient-reported perceived discomfort, such as changes in subjective feelings of vertigo (dizziness or spinning sensation) and the frequency of nausea and vomiting in patients after specific medical procedures. Findings were mixed across these trials, and the evidence quality varies across studies. An important limitation is that this evidence often describes group patterns based on studies using different medication forms (e.g., tablets or injections), meaning the results apply only to the populations and formulations studied, and there is limited information specifically linking these findings to the medicated chewing gum dosage form.


Evidence Gaps and Areas of Uncertainty

Studies primarily focused on prevention and have provided limited insight into research exploration of managing symptoms once motion sickness has already started. Follow-up durations were limited to the short time interval of a single motion event, meaning that evidence related to repeated, long-term use is not fully established. Data for certain groups remain insufficient, including research concerning outcomes in the pediatric population (children) or in older adults.

Key Studies & References DIMENHYDRINATE TABLETS, USP 50 mg - DailyMed (FDA-supported Monograph)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Travelgum (FAQ)


Q: How quickly does Travelgum start working?

The onset of action for dimenhydrinate is generally described in official sources as occurring within 30 minutes to an hour after use. The medicated chewing gum dosage form is formulated for absorption through the lining of the mouth, which is intended to facilitate a rapid onset.


Q: How long does the effect of Travelgum usually last?

Official product information suggests the duration of effect for dimenhydrinate typically lasts for several hours. This time frame aligns with the product's recommended minimum time between doses, which is 3 to 4 hours.


Q: Can I chew Travelgum while I am already feeling sick from motion?

Official product information indicates that the active ingredient dimenhydrinate is intended for both the prevention and relief of symptoms like nausea, vomiting, and vertigo. Therefore, while often used before travel, it is also described for use once symptoms have begun.


Q: Is it true that Travelgum should be chewed for a specific amount of time?

Official instructions for the medicated chewing gum dosage form describe that the gum should be chewed actively for 5 to 10 minutes. This defined period is necessary to ensure the proper release and absorption of the active substance through the oral mucosal route.


Q: Does Travelgum have any effect on driving ability?

Regulatory labels warn that Travelgum may cause marked drowsiness and could potentially impair the ability to perform tasks that require mental alertness. Caution is advised regarding activities such as driving a motor vehicle.


Q: How long after using Travelgum should I wait before operating machinery?

Due to the potential for drowsiness and impaired concentration, official safety data advises caution against operating dangerous machinery following use. The decision to resume such activities should be made with caution, taking into account that the sedating effects of the drug may persist.


Q: Is Travelgum available without a prescription?

Dimenhydrinate, the active ingredient in Travelgum, is widely classified and available as an Over-The-Counter (OTC) medication in many jurisdictions. This classification means it does not require a prescription for purchase.


Q: Is Travelgum the same type of medication as Dramamine?

Travelgum and Dramamine contain the exact same active substance, Dimenhydrinate. Both preparations are classified in the same pharmacological category as a first-generation antihistamine and anti-emetic (an anti-nausea agent).


Q: Can I drink coffee or caffeine while using Travelgum?

Travelgum contains 8-chlorotheophylline, which is chemically related to caffeine and is included to counter sedation. While specific universal warnings about coffee may vary, some regulatory sources suggest being aware of potential additive effects when combining it with products containing caffeine.


Q: Are there scientific studies confirming the effectiveness of Travelgum?

The effectiveness of the active ingredient, dimenhydrinate, for motion sickness is supported by existing clinical and research data. This body of evidence is used by regulatory agencies as the basis for the drug's approved indications, confirming its role in the prevention and relief of symptoms.


Q: Why do some people prefer chewing gum for motion sickness instead of swallowing a tablet?

Travelgum is a unique dosage form designed for drug delivery via the oral mucosal route, which allows the active ingredient to be absorbed through the lining of the mouth. This method is often noted as a convenient, water-free administration option.


Q: Can Travelgum be used for vertigo or dizziness unrelated to travel?

Official regulatory indications for the active ingredient often include the prevention and relief of vertigo (a sensation of dizziness or spinning) associated with various clinical situations, such as labyrinthine disturbances. This suggests that its documented use may extend beyond motion sickness alone.


Q: Is Travelgum addictive?

Regulatory documents acknowledge that the active ingredient, dimenhydrinate, has a known potential for substance abuse. The misuse of the product, especially in high amounts, is associated with the potential development of tolerance and dependence.


Q: Is it necessary to use Travelgum only when traveling?

While motion sickness related to travel is the primary indication, official documents also include the drug's use for vertigo and nausea/vomiting associated with other causes. Therefore, its documented use may occur outside the context of travel.


Q: What should I do if I accidentally chew and swallow the gum?

In the event of accidental ingestion or suspected overdose, official safety information recommends contacting a Poison Control Center or seeking immediate medical attention. While the gum base is inert, the active ingredient is then absorbed systemically.


Q: What happens if I forget to use Travelgum before a trip?

The first dose is typically recommended before travel for prevention. However, since regulatory documents indicate the drug is intended for both prevention and relief of symptoms, a dose can still be taken once symptoms like nausea or vomiting have started.


Q: Can Travelgum be given to a child under two years old?

No. The use of dimenhydrinate is absolutely prohibited (contraindicated) in children under 2 years of age. This restriction is based on official safety data and general concerns regarding the use of this drug in this specific age group.


Q: Does Travelgum lose effectiveness if stored in a warm car?

Official product information requires storage at a controlled room temperature and away from excess heat. Exposure to temperatures outside of the recommended range, such as in a warm car, is described in official documentation as potentially compromising the drug's quality.


Q: Does Travelgum interact with herbal supplements?

Although specific interactions with every herbal product are not universally documented, general regulatory guidance for antihistamines suggests being cautious with herbal remedies or supplements that may cause similar effects, such as sleepiness or dry mouth.

Advertisements

How should Travelgum be stored and disposed of?

Storage and Disposal of Travelgum

Official regulatory labeling dictates specific conditions for storing and disposing of Dimenhydrinate chewing gum to maintain product stability and safety.

Storage Requirements

  • Temperature: Store at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F), and away from excess heat.
  • Protection: The product must be kept in its original container, tightly closed, and stored in a dry location to protect it from moisture.
  • Child Safety: The medicine must be stored out of the sight and reach of children and kept in a safe, secured location.

Disposal Instructions

Unused or expired Dimenhydrinate should not be flushed down the toilet or disposed of in the household trash. The recommended method is to use an official drug take-back program or dispose of the medicine according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Travelgum found in:

A-Z Index: